US reverses stance, backs giving poorer countries access to Covid-19 vaccine patents, tech

US reverses stance, backs giving poorer countries access to Covid-19 vaccine patents, tech
US reverses stance, backs giving poorer countries access to Covid-19 vaccine patents, tech

Hello and welcome to the details of US reverses stance, backs giving poorer countries access to Covid-19 vaccine patents, tech and now with the details

Nevin Al Sukari - Sana'a - Biden has made fighting the coronavirus a top priority of his administration and the rollout of vaccines in the United States has led to a decline in case numbers and deaths. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


WASHINGTON, May 6 ― President Joe Biden yesterday threw his support behind waiving intellectual property rights for Covid-19 vaccines, bowing to mounting pressure from Democratic lawmakers and more than 100 other countries, but angering pharmaceutical companies.

Biden voiced his support for a temporary waiver ― a sharp reversal of the previous US position ― after a speech at the White House, followed swiftly by an official statement from his chief trade negotiator, Katherine Tai.

“This is a global health crisis, and the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures,” Tai said in a statement, amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.

Shares in a number of makers of vaccines for Covid-19 tumbled on the news. Two of the biggest vaccine makers are US companies ― Moderna Inc and Pfizer Inc.

Biden's move won praise from the head of the World Health Organisation, Tedros Adhanom Ghebreyesus, who called it a “MONUMENTAL MOMENT IN THE FIGHT AGAINST #COVID19” on Twitter.

The Biden administration told pharmaceutical companies ― which have reported sharp revenue and profit gains during the crisis ― about its plans ahead of the announcement, a senior administration official said.

The pharmaceutical industry's biggest lobby group warned that Biden's unprecedented step would undermine the companies' response to the pandemic and compromise safety.

Biden, who backed a waiver during the 2020 presidential campaign, has made fighting the coronavirus a top priority of his administration and the rollout of vaccines in the United States has led to a decline in case numbers and deaths.

The Democratic president, who campaigned on a promise to re-engage with the world after four years of contentious relations between former President Donald and US allies, has come under intensifying pressure to share US vaccine supply and technology to fight the virus around the globe.

His decision comes amid a devastating outbreak in India, which accounted for 46 per cent of the new Covid-19 cases recorded worldwide last week, and signs that the outbreak is spreading to Nepal, Sri Lanka and other neighbours.

Negotiations take time

Yesterday's statement paved the way for what could be months of negotiations to hammer out a specific waiver plan. WTO decisions require a consensus of all 164 members.

Tai cautioned deliberations would take time. The United States would also continue to push for increased production and distribution of vaccines around the world, she said.

The United States and several other countries previously blocked negotiations at the WTO about a proposal led by India and South Africa to waive protections for some patents and technology and boost vaccine production in developing countries.

Critics of the waiver say producing mRNA vaccines is complex and setting up production at new facilities would divert resources from efforts to boost production at existing sites.

Tai spoke yesterday with several foreign counterparts and some US lawmakers to explain the shift in the US approach, an administration source said.

The US government poured billions of dollars into research and advance purchases for Covid-19 vaccines last year when the shots were still in the early stages of development and it was unclear which, if any, would prove to be safe and effective at protecting against the virus.

Yesterday's move allows Washington to be responsive to the demands of the left and developing countries, while using WTO negotiations to narrow the scope of the waiver, said one source familiar with the deliberations. It also buys time to boost vaccine supplies through more conventional means.

Dr. Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, said the patent waiver “amounts to the expropriation of the property of the pharmaceutical companies whose innovation and financial investments made the development of Covid-19 vaccines possible in the first place.”

But proponents say the pharmaceutical companies will suffer only minor losses because any waiver would be temporary ― and they will still be able to sell follow-on shots that could be required for years to come.

Pfizer said on Tuesday it expects Covid-19 vaccine sales of at least US$26 billion (RM107 billion) this year and that demand for the shots from governments around the world fighting to halt the pandemic could contribute to its growth for years to come. ― Reuters

These were the details of the news US reverses stance, backs giving poorer countries access to Covid-19 vaccine patents, tech for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV US senators in Taiwan and announce vaccine donation
NEXT Alpha, Beta, Gamma, Delta — WHO uses Greek alphabet to name COVID-19 variants